A closer look at immune-mediated myocarditis in the era of combined checkpoint blockade and targeted therapies

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

E. Eisenhauer, P. Therasse, Jan Bogaerts et al. · European Journal of Cancer · 2008 · 29.5K citations

Medicine, Oncology, Treatment Planning +14

Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline

Julie R. Brahmer, Christina Lacchetti, Bryan J. Schneider et al. · Journal of Clinical Oncology · 2018 · 3.7K citations · Full text

Life Sciences, Immunology, Oncology +17

Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma

Brian I. Rini, Elizabeth R. Plimack, V.P. Stus et al. · New England Journal of Medicine · 2019 · 3.4K citations · Full text

Medicine, Oncology, Pharmacology +9

Cardiovascular Magnetic Resonance in Myocarditis: A JACC White Paper

Matthias G. Friedrich, Udo Sechtem, Jeanette Schulz‐Menger et al. · Journal of the American College of Cardiology · 2009 · 2.5K citations · Full text

Medicine, Cardiology, Radiology +14

Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

John B.A.G. Haanen, Franck Carbonnel, Caroline Robert et al. · Annals of Oncology · 2017 · 2.4K citations · Full text

Pharmacy, Immunology, Oncology +12